The ATP-competitive JNK inhibitor SP600125 was sufficient to inhibit cell viability, migration and invasion of glioblastoma cells through decreasing the phosphorylation levels of both c-Jun and Akt. The gene discussed is JUN; the disease is glioblastoma.